ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,554Medicare Part D Prescriptions Filled, Including Refills

Rank: 254 out of 1844

$609K Total Retail Price of All Prescriptions

Rank: 230 out of 1844

385 Patients Receiving at Least One Drug in Part D
89%Patients 65 Years and Older
50% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Indiana
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

7% of this provider’s 385 patients filled at least one prescription for a schedule three drug, compared to an average of 15%.

Risky Drugs to Seniors

4% of this provider’s 8,884 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

31% of this provider’s prescriptions were for brand-name drugs, compared to an average of 24%.

Prescription Price

$64 was the average price of a prescription from this provider, compared to $60 among peers.

Prescriptions per Patient

25 is the average number of prescriptions (including refills) per patient, compared to an average of 20.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Indiana
NAPROXEN 300 277 1 87
SIMVASTATIN 300 275 1 3
FUROSEMIDE 278 255 3 7
METOPROLOL TARTRATE 238 235 4 11
POTASSIUM CHLORIDE 229 229 5 16
LISINOPRIL 229 219 5 4
LEVOTHYROXINE SODIUM 223 215 7 1
CEFADROXIL 220 198 8 258
BENICAR HCT 208 196 9 244
OMEPRAZOLE 203 192 10 5
AMLODIPINE BESYLATE 195 191 11 6
WARFARIN SODIUM 192 185 12 13
LEVOFLOXACIN 169 156 13 78
GLYBURIDE 167 154 R 14 100
TRAMADOL HCL 151 138 15 18
TRIAMTERENE-HCTZ 147 139 16 48
CEPHALEXIN 146 133 17 56
ATORVASTATIN CALCIUM 127 118 18 12
AZITHROMYCIN 123 119 19 37
PANTOPRAZOLE SODIUM 110 105 20 32
METOPROLOL SUCCINATE 104 102 21 14
NEXIUM 99 70 22 31
FENTANYL 95 71 S2 23 66
HYDROXYZINE HCL 95 94 R 23 164
CLOPIDOGREL 94 88 25 34
HYDROCODONE-ACETAMINOPHEN 93 80 S3 26 2
ADVAIR DISKUS 90 90 27 51
SERTRALINE HCL 87 75 28 21
ALLOPURINOL 86 83 29 29
DONEPEZIL HCL 81 81 30 26
CIPROFLOXACIN HCL 80 76 31 62
CARVEDILOL 80 77 31 22
SYNTHROID 77 62 33 55
METFORMIN HCL 77 76 33 8
JANUMET 74 66 35 211
PRAVASTATIN SODIUM 70 68 36 10
CYMBALTA 69 65 37 36
PREDNISONE 66 57 38 40
KLOR-CON M20 66 66 38 54
COMBIVENT 65 65 40 131
ISOSORBIDE MONONITRATE ER 62 62 41 59
SPIRIVA 62 61 41 57
RISPERIDONE 61 58 43 65
ESCITALOPRAM OXALATE 60 46 44 52
GABAPENTIN 60 56 44 15
KLOR-CON 8 58 58 46 205
PROAIR HFA 57 57 47 45
PLAVIX 56 55 48 61
ATENOLOL 55 49 49 17
HYDROCHLOROTHIAZIDE 53 53 50 9
MECLIZINE HCL 52 49 51 142
DIOVAN 50 50 52 58
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Sept. 13, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.